share_log

BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In A Phase 2 Social Anxiety Disorder Prevail Study

BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In A Phase 2 Social Anxiety Disorder Prevail Study

Brief-Bionomics獲得FDA批准在社交焦慮障礙流行研究中評估BNC210的IND
reuters ·  2021/11/01 06:16

Nov 1 (Reuters) - Bionomics Ltd BNO.AX :

路透11月1日電-Bionomics Ltd BNO.AX:

* BIONOMICS RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF BNC210 IN A PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY

*Bionomics獲得FDA批准在社交焦慮症流行研究中評估BNC210的IND

* BIONOMICS LTD - PREVAIL STUDY REMAINS ON TARGET TO INITIATE BY END OF 2021 AND IS EXPECTED TO READ OUT TOPLINE DATA BY END OF 2022

*Bionomics Ltd-Prevail研究仍按目標在2021年底啟動,預計在2022年底讀出背線數據

Source text for Eikon: ID:nPn3d6VMYa Further company coverage: BNO.AX

Eikon的源文本:ID:nPn3d6VMYa進一步的公司報道:BNO.AX

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論